Genovate Biotechnology CO., LTD.
Climate Impact & Sustainability Data (2023)
Reporting Period: 2023
Environmental Metrics
ESG Focus Areas
- Environmental
- Social
- Governance
Environmental Achievements
- Replaced heavy oil with natural gas for boiler fuel, reducing environmental impact.
- Implemented waste sorting and paper recycling policies.
Social Achievements
- Provided employees with comprehensive annual health checkups, including cancer screening.
- Offered group insurance (including spouse/children coverage) and various welfare benefits.
- Maintained harmonious labor-management relations through regular meetings and employee incentives.
- Achieved “Accredited Healthy Workplace” designation from the Health Promotion Administration of MOHW.
Governance Achievements
- Established an audit committee and a remuneration committee.
- Implemented a comprehensive internal control system.
- Consistently aligned planning and business strategies with corporate governance principles.
- Completed board of directors' performance evaluation with a high overall score.
Climate Goals & Targets
Long-term Goals:
- Continuously generate profits, maintain sustainable operations, and fulfill corporate social responsibilities.
Medium-term Goals:
- Implement the innovative R&D mode of industry-academia collaboration and industry alliances.
- Enhance the company's value through strategic alliances.
Short-term Goals:
- Invest in factory software and hardware to enhance PIC/S GMP production quality and expand production capacity.
- Reduce raw material costs and improve production processes.
- Expand into other biomedical product fields.
Environmental Challenges
- High risk in developing new drugs.
- Long product development schedules.
- Tightening of drug price reimbursements by the National Health Insurance.
- Lack of experience in supplying and selling medicines to large hospitals.
- Global supply chain remains turbulent due to geopolitical rivalries and conflicts.
Mitigation Strategies
- Develop new drugs with lower risks, seeking joint development partners and government subsidies.
- Effectively control product development schedules and collaborate with international pharmaceutical companies.
- Actively expand into the international market and develop non-reimbursable items.
- Cultivate relationships with main department doctors and patient associations.
- Establish a flexible procurement system and conduct an exhaustive search for raw material suppliers.
- Invest in new automated machinery and tools to enhance the production process.
Supply Chain Management
Supplier Audits: 203 suppliers audited in 2023
Responsible Procurement
- Diverse procurement strategy with at least two suppliers for each main raw material.
- Strict quality standards, inspection, and evaluation procedures for upstream and downstream manufacturers.
Climate-Related Risks & Opportunities
Physical Risks
- Extreme weather events, factory damage, production line shutdowns
Transition Risks
- Supply chain disruptions
Opportunities
- Development of energy-efficient products
Reporting Standards
Frameworks Used: IFRS
Certifications: PIC/S GMP
Third-party Assurance: PricewaterhouseCoopers Taiwan
Sustainable Products & Innovation
- PMR (Anti-intermittent claudication drug)
- GX17 immunomodulatory drugs
Awards & Recognition
- Accredited Healthy Workplace designation from the Health Promotion Administration of MOHW